Brooktree Capital Management Buys 12,635 Shares of DexCom, Inc. $DXCM

Brooktree Capital Management increased its stake in DexCom, Inc. (NASDAQ:DXCM) by 43.2% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 41,880 shares of the medical device company’s stock after purchasing an additional 12,635 shares during the quarter. DexCom makes up 1.8% of Brooktree Capital Management’s investment portfolio, making the stock its 14th largest holding. Brooktree Capital Management’s holdings in DexCom were worth $2,818,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its holdings in shares of DexCom by 257.7% during the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock worth $1,290,000 after buying an additional 11,946 shares during the period. Integrated Wealth Concepts LLC lifted its position in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares during the last quarter. Empowered Funds LLC boosted its holdings in DexCom by 5.4% during the first quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock valued at $577,000 after acquiring an additional 436 shares during the period. Focus Partners Wealth boosted its holdings in DexCom by 13.2% during the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after acquiring an additional 841 shares during the period. Finally, Concurrent Investment Advisors LLC acquired a new stake in shares of DexCom in the second quarter valued at about $372,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. TD Cowen decreased their target price on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research note on Friday, October 31st. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, November 16th. Robert W. Baird set a $87.00 price objective on shares of DexCom in a research note on Friday. Canaccord Genuity Group set a $95.00 target price on shares of DexCom and gave the company a “buy” rating in a research note on Friday. Finally, Sanford C. Bernstein reissued an “outperform” rating and issued a $86.00 price target (up from $84.00) on shares of DexCom in a report on Friday, January 9th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $85.27.

DexCom News Roundup

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

DexCom Trading Up 7.6%

Shares of DXCM stock opened at $70.02 on Monday. The firm has a fifty day moving average of $69.03 and a 200-day moving average of $69.47. The stock has a market cap of $26.95 billion, a price-to-earnings ratio of 33.34, a P/E/G ratio of 1.25 and a beta of 1.49. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The firm’s revenue for the quarter was up 13.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.45 earnings per share. On average, equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.